12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Transactions closing on February 27 or later will be subject to increased HSR Act jurisdictional and...
Read More >
On January 13, 2020, the Committee on Foreign Investment in the United States (CFIUS) issued final r...
Read More >
In today’s edition of Daily Compliance News: Congress takes aim at NCAA. (WSJ) Massive Cambridge A...
Read More >
The New York Legislature on June 19, 2019 unanimously passed expansive new protections for protected...
Read More >
New Jersey Governor Phil Murphy just issued an executive order lifting some of the existing restrict...
Read More >
On June 18, 2019, in Marchand v. Barnhill, the Delaware Supreme Court, in an opinion written by Chie...
Read More >